A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.
about
Inflammation in depression: is adiposity a cause?Depression and suicide ideation in chronic hepatitis C patients untreated and treated with interferon: prevalence, prevention, and treatmentPsychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implicationsAntidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: a systematic review and meta-analysisDepression during pegylated interferon-alpha plus ribavirin therapy: prevalence and predictionInterferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disordersSelective serotonin re-uptake inhibitors and the risk of bleedingAssociation of Baseline Sleep Quality With Trajectories of Depressive Symptoms in Patients Undergoing Interferon TreatmentCan antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?Association of Changes in Mood Status and Psychosocial Well-Being with Depression During Interferon-Based Treatment for Hepatitis C.Enhanced cognitive function and antidepressant-like effects after krill oil supplementation in rats.Dissociative symptoms reflect levels of tumor necrosis factor alpha in patients with unipolar depression.Depression and Chronic Liver Diseases: Are There Shared Underlying Mechanisms?Recurrence of depressive disorders after interferon-induced depression.Psychiatric clearance for patients started on interferon-alpha-based therapies.Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatmentMental and physical symptoms associated with lower social support for patients with hepatitis C.Mechanisms for interferon-α-induced depression and neural stem cell dysfunction.Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha.Neuropsychiatric adverse effects of interferon-alpha: recognition and management.Major depressive disorder in hepatitis C: an open-label trial of escitalopramEating ourselves to death (and despair): the contribution of adiposity and inflammation to depressionEvaluation of depression as a risk factor for treatment failure in chronic hepatitis C.Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeksNeurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetineHepatitis C in European prisons: a call for an evidence-informed responsePegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C.Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorderProphylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trialNo increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C.Management of Hepatitis C Antiviral Therapy Adverse Effects.A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase.The fiery landscape of depression: A review of the inflammatory hypothesis.Minocycline treatment ameliorates interferon-alpha- induced neurogenic defects and depression-like behaviors in mice.Psychiatric treatment considerations with direct acting antivirals in hepatitis CPsychiatric care of the patient with hepatitis C: a review of the literature.Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.Prevention and treatment of hepatitis C in injection drug users.The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.General medical with depression drugs associated.
P2860
Q24635451-5E2350CE-49FD-4343-86FD-8382F6A06659Q26783698-5F529C18-314B-4C95-BD97-B65AB820A639Q26798477-7667BF41-74E8-4822-BABB-B98E301570EDQ26864986-6434C711-1A73-4EDD-9F91-0ED9FAED7E67Q27477533-2F4612AB-7674-473B-A3FC-DABD2CADDA14Q27477998-71949D7E-D662-4D2B-BADA-49D71C1F5FEDQ28211440-635C13AF-BB7C-49B2-8A59-F6B2A135BD84Q28387292-3E219B21-022D-43FD-9408-BBB697A1D7F0Q28534735-5C6C91A2-C7D8-451C-99A9-BF031230D54DQ30355874-2DF4A31C-B63D-4553-9A5D-2A93C3B78164Q30538444-CE1E1996-46BD-4148-9DF9-D4A4350C1EFBQ33559292-544EF35A-1B59-4BD4-B2BA-28634C0D6753Q33645706-086CC3D2-0E03-416A-90F5-2B68B88F0CD7Q33707679-60373909-BF98-46D6-ABAE-E9741DDC201EQ33708662-11C4D370-FB4A-418E-B2E6-4FDFA71EBF9DQ33816643-44C9AD73-12B1-478E-A7F6-658069167E1BQ33867829-19DF0C8E-41E4-4FA2-ACD3-A77DFFFE2D4FQ33949107-64A5B994-CDAC-44A3-AF7D-511A3661B41AQ34026599-F2D579E0-1B79-475C-8F03-9A5DD994AD51Q34081783-4184ED9B-599A-42C4-9763-89A8115FBCFBQ34084151-CA9739AB-BA49-480C-BAE0-792B3E745FE1Q34090453-EB6CA80C-4E22-4C38-9B06-61177B2FDE03Q34129599-9C5BCEA8-D574-4C3B-902D-B285B6C2917EQ34225384-CF2FC399-BC47-46C3-8B14-34B2B91D9C59Q34256005-767296AC-4A34-4C38-B7EB-F36E78662F93Q34260664-7E2F48DD-D89F-47D8-9238-1BBBED854A2AQ34262438-3B1535DA-C5FF-4643-962C-84BFF02498A5Q34330471-BD7AB6CC-4C22-4161-A6D8-621082529D8FQ34365319-D662A180-C9FF-4026-BF8C-4D745163BF6AQ34511200-63272A39-31C7-43A1-A2C6-F3D28682FB62Q34538771-FAD258DC-B9B3-4833-A127-060BC0BF7128Q34631232-3D0DBA28-9D68-44D2-AB01-5D04D815E34EQ34658493-1915B3D2-6916-4BCA-91EC-EDA92B02F983Q34667917-F037A75C-1027-4B07-83D6-C27C1CC018D2Q34721628-97BFAECD-48EE-4C65-9091-83F871CC6ED0Q34743058-3B482ED0-0112-4D85-8435-569AE399AD2BQ34795051-90337E6A-2509-46D1-BE4A-5336E45C0552Q34984130-9E551F55-8173-45F1-B752-891EDAC1CB07Q34996746-587CCAFB-70CD-4C6C-931E-BC341158F096Q35000814-5D024313-4F47-4622-8C8E-F5FC8C207A43
P2860
A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
A prospective study of the inc ...... in patients with hepatitis C.
@en
A prospective study of the inc ...... in patients with hepatitis C.
@nl
type
label
A prospective study of the inc ...... in patients with hepatitis C.
@en
A prospective study of the inc ...... in patients with hepatitis C.
@nl
prefLabel
A prospective study of the inc ...... in patients with hepatitis C.
@en
A prospective study of the inc ...... in patients with hepatitis C.
@nl
P2093
P2860
P356
P1433
P1476
A prospective study of the inc ...... r in patients with hepatitis C
@en
P2093
Schultz RL
Thornton AJ
P2860
P2888
P304
P356
10.1038/SJ.MP.4001119
P407
P577
2002-01-01T00:00:00Z